HHLA2 silencing in mice resulted in a slightly decreased incidence of HCC (6/10 compared with 8/10 in WT mice), nodular metastases, and CD31 (a vascular marker) expression. The gene discussed is HHLA2; the disease is hepatocellular carcinoma.